Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

@article{Barradell1994CyproteroneAR,
  title={Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.},
  author={Lee Barradell and Diana Faulds},
  journal={Drugs & aging},
  year={1994},
  volume={5 1},
  pages={
          59-80
        }
}
Cyproterone (cyproterone acetate) is a steroidal antiandrogenic agent that inhibits the action of adrenal and testicular androgens on prostatic cells. Additionally, its progestogenic activity causes a centrally mediated reduction in testicular secretion of androgens. Studies have demonstrated the effectiveness of cyproterone monotherapy in patients with prostate cancer, and for those in whom orchiectomy is not an acceptable option cyproterone may be a useful alternative. In addition, the drug… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

  • David Gillatt
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • 2006
VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases.